Recently, monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed death-1 (PD-1) receptor, and its ligand (PD-L1) have achieved encouraging antitumor effects in STAD patients [5]. Here, CTLA4 is linked to gastric adenocarcinoma.